June 30, 2021
1 min read

 Covaxin effective against both Alpha, Delta variants: US NIH

COVAXIN comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus…reports Asian Lite News

The National Institute of Health (NIH) in the United States has found that Bharat Biotech’s COVAXIN vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of COVID-19.

The top health research institute said that an adjuvant developed with funding from the NIH has contributed to the success of the “highly efficacious” COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.

“Results from two studies of blood serum from people who had received COVAXIN suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively,” NIH said in a statement.

The adjuvant used in COVAXIN, Alhydroxiquim-II, was discovered and tested in the laboratory by the biotech company ViroVax LLC of Lawrence, Kansas with support exclusively from the NIAID Adjuvant Development Program, NIH said.

ALSO READ: ‘FDA decision on Covaxin has no bearing on us’

The adjuvant comprises a small molecule attached in a unique way to Alhydrogel, a substance frequently called alum that is the most commonly used adjuvant in vaccines for people.

“Ending a global pandemic requires a global response,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH. “I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious COVID-19 vaccine available to people in India.”

COVAXIN comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus. Published results from a Phase 2 trial of the vaccine indicate that it is safe and well-tolerated.

Unpublished interim results from the Phase 3 trial indicate that the vaccine has 78 per cent efficacy against symptomatic disease, 100 per cent efficacy against severe COVID-19, including hospitalization, and 70 per cent efficacy against asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19. (ANI)

ALSO READ: Covaxin trials on children set to begin

Previous Story

Burmese grapes from Assam exported to Dubai

Next Story

Modi holds high-level meet on security issues

Latest from -Top News

World Bank Warns of Growing Poverty in Pakistan

Instead of concentrating on rural development to reduce poverty, the Pakistan government has been focused more on increasing defence expenditure….reports Asian Lite News The World Bank has voiced deep concern over Pakistan’s

Hasina Faces Arrest in War Crimes Probe

Two formal charges were submitted by the ICT prosecution against Hasina and her security and defence advisor, Tarique Ahmed Siddique….reports Asian Lite News Bangladesh’s International Crimes Tribunal (ICT) on Wednesday issued arrest

Peace in Afghanistan Vital, Says India

The Indian delegation at the meeting was led by Ambassador to Russia Vinay Kumar who expressed support for independent, peaceful and stable Afghanistan….reports Asian Lite News On Tuesday, India reaffirmed that a

India, Qatar Strengthen Trade Ties

Goyal expressed optimism about the growing economic engagement between the two countries, stating, “Glad to meet Ahmed bin Mohammed Al-Sayed….reports Asian Lite News Union Minister of Commerce and Industry Piyush Goyal met
Go toTop

Don't Miss

Covaxin gets emergency use approval for kids aged 2-18 years

Public health experts says move can turn out to be

Covaxin, Sputnik V jabs red-flagged in US

Campuses are proposing different measures, out of which the more